The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1744-1754

  Yu, Peter T ^a   Babicky, Michele ^a   Jaquish, Dawn ^a   French, Randy ^a   Marayuma, Karly ^a   Mose, Evangeline ^a   Niessen, Sherry ^b   Hoover, Heather ^b   Shields, David ^c   Cheresh, David ^c   Cravatt, Benjamin F ^b   Lowy, Andrew M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

integrin beta 4; pancreatic cancer; plectin; RON receptor

Indexed keywords

BETA4 INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PLECTIN; PROTEIN RON; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEMIDESMOSOME; HUMAN; HUMAN CELL; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; FLUORESCENT ANTIBODY TECHNIQUE; HEMIDESMOSOMES; HUMANS; INTEGRIN BETA4; KIDNEY; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PLECTIN; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; WOUND HEALING;

EID: 84865312885     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27447     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM,. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 2010; 70: 1130-40.
3. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM,. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007; 67: 6075-82. (Pubitemid 47037486)
4. Sonnenberg A, Liem RK,. Plakins in development and disease. Exp Cell Res 2007; 313: 2189-203. (Pubitemid 46842974)
5. Leung CL, Green KJ, Liem RK,. Plakins: a family of versatile cytolinker proteins. Trends Cell Biol 2002; 12: 37-45. (Pubitemid 34164155)
6. Litjens SH, de Pereda JM, Sonnenberg A,. Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol 2006; 16: 376-83. (Pubitemid 44062316)
7. Bausch D, Thomas S, Mino-Kenudson M, Fernandez-Del Castillo C, Bauer TW, Williams M, Warshaw AMD, Thayer SP, Kelly KA,. Plectin as a novel biomarker for pancreatic cancer. Clin Cancer Res 2010; 17: 302-9.
8. Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, Depinho RA, Mahmood U, Weissleder R,. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 2008; 5: e85.
9. Vezeridis MP, Txanakakis GN, Meitner PA, Doremus CM, Tibbetts LM,. In vivo selection of a highly metastatic cell line of a human pancreatic carcinoma in the nude mouse. Cancer 1992; 69: 2060-3.
10. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ,. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999; 1: 50-62.
11. Washburn MP, Wolters D, Yates JR 3rd., Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 242-7. (Pubitemid 32220565)
12. Gregor M, Zeold A, Oehler S, Marobela KA, Fuchs P, Weigel G, Hardie DG, Wiche G,. Plectin scaffolds recruit energy-controlling AMP-activated protein kinase (AMPK) in differentiated myofibres. J Cell Sci 2006; 119: 1864-75. (Pubitemid 43811012)
13. Lunter PC, Wiche G,. Direct binding of plectin to Fer kinase and negative regulation of its catalytic activity. Biochem Biophys Res Commun 2002; 296: 904-10.
14. Koster J, van Wilpe S, Kuikman I, Litjens SH, Sonnenberg A,. Role of binding of plectin to the integrin beta4 subunit in the assembly of hemidesmosomes. Mol Biol Cell 2004; 15: 1211-23. (Pubitemid 38316228)
15. Osmanagic-Myers S, Wiche G,. Plectin-RACK1 (receptor for activated C kinase 1) scaffolding: a novel mechanism to regulate protein kinase C activity. J Biol Chem 2004; 279: 18701-10. (Pubitemid 38623294)
16. Ding Y, Zhang L, Goodwin JS, Wang Z, Liu B, Zhang J, Fan GH,. Plectin regulates the signaling and trafficking of the HIV-1 co-receptor CXCR4 and plays a role in HIV-1 infection. Exp Cell Res 2008; 314: 590-602.
17. Danilkovitch-Miagkova A,. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003; 3: 31-40. (Pubitemid 36119419)
18. Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG,. EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J Cell Biol 2001; 155: 447-58.
19. Trusolino L, Bertotti A, Comoglio PM,. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001; 107: 643-54. (Pubitemid 34014865)
20. Santoro MM, Gaudino G, Marchisio PC,. The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell 2003; 5: 257-71. (Pubitemid 37006470)
21. Dai Y, Siemann DW,. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010; 9: 1554-61.
22. Wilhelmsen K, Litjens SH, Kuikman I, Margadant C, van Rheenen J, Sonnenberg A,. Serine phosphorylation of the integrin beta4 subunit is necessary for epidermal growth factor receptor induced hemidesmosome disruption. Mol Biol Cell 2007; 18: 3512-22. (Pubitemid 47378689)
23. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM,. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 2007; 109: 1030-9. (Pubitemid 46435380)
24. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006; 66: 9162-70. (Pubitemid 44521136)
25. Frijns E, Sachs N, Kreft M, Wilhelmsen K, Sonnenberg A,. EGF-induced MAPK signaling inhibits hemidesmosome formation through phosphorylation of the integrin {beta}4. J Biol Chem 2010; 285: 37650-62.
26. Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM,. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 2011; 71: 1945-55.
27. Peace BE, Hill KJ, Degen SJ, Waltz SE,. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp Cell Res 2003; 289: 317-25. (Pubitemid 37117417)